Recurrent Meningioma
2
Pipeline Programs
3
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2025
2026
2027
2028
SandozLocal standard of Care
RayzeBioActinium Ac 225 DOTATATE RYZ101
Clinical Trials (2)
Total enrollment: 166 patients across 2 trials
177Lu-DOTATATE for Recurrent Meningioma
Start: Mar 2025Est. completion: Dec 2028136 patients
Phase 2Recruiting
RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
Start: Nov 2025Est. completion: Dec 202630 patients
Phase 1/2Suspended
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 166 patients
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.